FBIO Fortress Biotech Inc.

2.45
-0.01  -0%
Previous Close 2.46
Open 2.5
Price To Book 6.81
Market Cap 173,411,252
Shares 70,780,103
Volume 209,586
Short Ratio
Av. Daily Volume 429,990
Stock charts supplied by TradingView

NewsSee all news

  1. Mustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020

    NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  2. Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease

    NEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and

  3. Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

    FDA feedback supports plan to submit Biologics License Application (BLA) based on data from ongoing Phase 1 trialOne-third enrollment complete in cohort of patients with metastatic cutaneous squamous cell

  4. Journey Medical Corporation Recaps 2019 Growth

    Potent sales and marketing model drives continued commercial success of branded dermatology products Preliminary unaudited full-year 2019 net revenue expected to be between $33 million and $36 million SCOTTSDALE,

  5. Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children's Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders

    NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") today announced that Baergic Bio, Inc. ("Baergic"), a newly formed Fortress partner company, has entered into an exclusive

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 enrolment to be completed by end of 2020. Estimate data 1H 2021. BLA filing due 2021.
CK-101
Cutaneous Squamous Cell Carcinoma
Phase 1 MBIO IND to be filed 2H 2020.
MB-101
Glioblastoma
Phase 2b/3 trial to be initiated 1H 2020 with data due in 2021.
CAEL‐101
AL amyloidosis
Phase 2 data in adults due 2021.
CEVA101
Severe Traumatic Brain Injury
Phase 2 data in children due 2020.
CEVA101
Severe Traumatic Brain Injury
Rolling NDA submission expected to start in 2H 2020 and be completed in 1H 2021.
CUTX-101
Menkes disease
NDA filing announced December 11, 2019.
Intravenous (IV) tramadol
Postoperative pain following bunionectomy surgery
Phase 1/2 data presented at ASH December 7, 2019.
MB-107
X-linked Severe Combined Immunodeficiency (XSCID)
Phase 1 data presented at ASH December 8, 2019.
MB-106
B-cell Non-Hodgkin Lymphoma & Chronic Lymphocytic Leukemia (CLL)
Phase 3 trial to be initiated 1H 2020.
Triplex
Cytomegalovirus (CMV)
Phase 1/2 trial to be initiated late 2019 or 2020.
MB-104
Multiple myeloma
Phase 1 trial ongoing.
MB-103
HER2-Positive Breast Cancer with Brain Metastases
Phase 1 treatment has commenced - noted September 23, 2019.
MB-105
Prostate cancer
Phase 1 commencement of dosing announced October 24, 2019.
MB-108
Glioblastoma multiforme

Latest News

  1. Mustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020

    NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  2. Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease

    NEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and

  3. Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

    FDA feedback supports plan to submit Biologics License Application (BLA) based on data from ongoing Phase 1 trialOne-third enrollment complete in cohort of patients with metastatic cutaneous squamous cell

  4. Journey Medical Corporation Recaps 2019 Growth

    Potent sales and marketing model drives continued commercial success of branded dermatology products Preliminary unaudited full-year 2019 net revenue expected to be between $33 million and $36 million SCOTTSDALE,

  5. Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children's Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders

    NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") today announced that Baergic Bio, Inc. ("Baergic"), a newly formed Fortress partner company, has entered into an exclusive

  6. Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol

    NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced that it has

  7. Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency

    MB-107 preceded by low-dose busulfan conditioning continues to be well tolerated and results in development of functional immune system in newly diagnosed infants with XSCID Enhanced transduction procedure is

  8. Mustang Bio to Participate in the Evercore ISI 2nd Annual HealthCONx Conference

    NEW YORK, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  9. Fortress Biotech to Participate in December 2019 Investor Conferences

    NEW YORK, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and

  10. Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

    NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (NASDAQ:FBIOP) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential

  11. Checkpoint Therapeutics Announces Pricing of Public Offering of Common Stock

    NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pricing of its previously

  12. Checkpoint Therapeutics Announces Proposed Public Offering of Common Stock

    NEW YORK, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it is proposing to offer and

  13. Fortress Biotech Ranked in Top 10 of Deloitte's 2019 Technology Fast 500™

    NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and

  14. Fortress Biotech Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and

  15. Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  16. Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new pharmacokinetic and target

  17. Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage, immunotherapy and targeted oncology company, today announced financial results and recent

  18. Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual Meeting

    St. Jude Children's Research Hospital and the National Institutes of Health to present updated MB-107 clinical data for the treatment of X-linked severe combined immunodeficiency Fred Hutchinson Cancer Research Center

  19. Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today reported financial results

  20. Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

    NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, announced today that its Phase 1

  21. Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

    NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, announced today that its Phase 1

  22. Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

    NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, announced today that its Phase 1

  23. Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

    NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, announced today that its Phase 1

  24. Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma

    NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  25. Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma

    NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  26. Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma

    NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  27. Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma

    NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  28. Fortress Biotech to Participate in the 5th Annual Dawson James Small Cap Growth Conference

    NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and

  29. Mustang Bio Announces City of Hope Receives $4.1 Million in Grant Awards for Recently Opened First-of-Its-Kind Clinical Trial for Patients with Recurrent Malignant Glioma

    NEW YORK, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  30. Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology (ESMO) Congress 2019

    50% objective response rate observed in cutaneous squamous cell carcinoma (CSCC)40% objective response rate observed in non-small cell lung cancerWell-tolerated safety profile across all cohortsEnrollment ongoing to

  31. Checkpoint Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and

  32. Mustang Bio to Participate in October 2019 Investor Conferences

    NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  33. Fortress Biotech to Present at October 2019 Investor Conferences

    NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and

  34. Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope

    NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  35. Mustang Bio to Present at Scientific Conferences in September 2019

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  36. Fortress Biotech to Present at September 2019 Investor Conferences

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and

  37. Mustang Bio to Present at September 2019 Investor Conferences

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  38. Mustang Bio Announces License Agreement with CSL Behring for the Cytegrity™ Stable Producer Cell Line for the Production of MB-107 Lentiviral Gene Therapy

    NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  39. Mustang Bio and St. Jude Children's Research Hospital announce MB-107 lentiviral gene therapy for X-linked Severe Combined Immunodeficiency (XSCID) granted regenerative medicine advanced therapy (RMAT) designation from FDA

    RMAT designation follows positive Phase 1/2 clinical data published in the New England Journal of Medicine  Designation to facilitate expedited development and review of MB-107 for XSCID NEW YORK and MEMPHIS, Tenn.,